Targeted therapy in advanced well-differentiated neuroendocrine tumors

Related Experiment Video

Updated: Jun 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Chandrajit P Raut1, Matthew H Kulke

  • 1Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA. craut@partners.org

The Oncologist
|February 25, 2011
PubMed

Insights

New targeted therapies offer hope for advanced neuroendocrine tumors, a cancer type with limited treatment options. Research shows promising results with radiolabeled somatostatin analogs and pathway inhibitors.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Advanced neuroendocrine tumors (NETs) historically had limited effective treatment options.
  • Salvage surgery, liver-directed therapy, and cytotoxic chemotherapy show minimal impact in managing advanced NETs.
  • Somatostatin analogs are used for symptom control but lack cytotoxic intent.

Purpose of the Study:

  • To review recent advancements in targeted therapy for neuroendocrine tumors.
  • To highlight promising new treatment paradigms for drug-resistant NETs.

Main Methods:

  • Review of studies on novel therapeutic agents for advanced neuroendocrine tumors.
  • Evaluation of radiolabeled somatostatin analogs.
  • Assessment of inhibitors targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways.

Main Results:

  • Targeted therapies are emerging as new treatment paradigms for NETs.
  • Radiolabeled somatostatin analogs show promising efficacy.
  • Inhibitors of VEGF and mTOR pathways demonstrate encouraging results in NET management.

Conclusions:

  • Advances in targeted therapy are expanding treatment options for advanced neuroendocrine tumors.
  • Novel agents like radiolabeled somatostatin analogs and pathway inhibitors represent significant progress.
  • These developments offer new hope for patients with drug-resistant NETs.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...